Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers | Zendy

Akil Jackson | Zendy; A.D. Hill | Zendy; Rebekah Puls | Zendy; LJ Else | Zendy; Janaki Amin | Zendy; David Back | Zendy; Enmoore Lin | Zendy; Saye Khoo | Zendy; Sean Emery | Zendy; Roland Morley | Zendy; Brian Gazzard | Zendy; Marta Boffito | Zendy

Open Access

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

Author(s) -

Akil Jackson,

A.D. Hill,

Rebekah Puls,

LJ Else,

Janaki Amin,

David Back,

Enmoore Lin,

Saye Khoo,

Sean Emery,

Roland Morley,

Brian Gazzard,

Marta Boffito

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq468

Subject(s) - lopinavir , ritonavir , pharmacokinetics , lopinavir/ritonavir , regimen , medicine , tolerability , pharmacology , trough concentration , gastroenterology , adverse effect , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , immunology

Data suggest that some licensed antiretroviral doses could be reduced. We assessed the safety, tolerability and pharmacokinetics of lopinavir/ritonavir at doses of 400/100, 200/150 and 200/50 mg twice daily in HIV-negative volunteers (http://clinicaltrials.gov/ct2/show/NCT00985543).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research